Efficacy analysis of CDK4/6 inhibitors (CDKi) plus endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

被引：0

作者：

Tolosa Ortega, Pablo

Pascual, Tomas

Hernando, Cristina

Servitja, Sonia

Fernandez-Abad, Maria

Braso-Maristany, Fara

Benitez Fuentes, Javier David

Lema, Laura

Parrilla Rubio, Lucia

Ruano, Yolanda

Maria Roncero, Ana

Sanchez-Bayona, Rodrigo

Alva Bianchi, Manuel

Villacampa, Guillermo

Cobos-Fernandez, Maria Angeles

del Rocio Moreno, Maria

Canes, Jordi

Salvador, Fernando

Prat, Aleix

Ciruelos, Eva M.

机构：

[1] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[2] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Dept Med Oncol,SOLTI Breast Canc Cooperat Grp, Barcelona, Spain

[3] Hosp Clin Univ Valencia, Dept Med Oncol, Biomed Res Inst INCLIVA, Valencia, Spain

[4] Hosp Mar, Barcelona, Spain

[5] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[6] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[7] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain

[8] Hosp Clin San Carlos, Dept Med Oncol, IdISSC, Madrid, Spain

[9] 12 Octubre Univ Hosp, Madrid, Spain

[10] Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain

[11] Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain

[12] SOLTI Canc Res Grp, Barcelona, Spain

[13] Univ Hosp 12 Octubre, Dept Med Oncol, Breast Canc Unit, GEICAM Spanish Breast Canc Grp, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1065

引用

页数：1

共 50 条

[31] ctDNA-based DNADX in hormone receptorpositive and HER2-negative (HR+/HER2-) advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
Braso-Maristany, Fara
Cortes, Javier
Perez-Garcia, Jose Manuel
Vega-Leon, Rosario
Pare, Laia
Villacampa, Guillermo
Matito, Judit
Pardo, Francisco
Gomez-Rey, Marina
Mancino, Mario
Martinez-Garcia, Elena
Gallardo, Carmen Mora
Mina, Leonardo
Dalenc, Florence
Bellet-Ezquerra, Meritxell
Ruiz-Borrego, Manuel
Gil-Gil, Miguel
Schmid, Peter
Perou, Charles M.
Parker, Joel S.
Villagrasa, Patricia
Vivancos, Ana
Prat, Aleix
Llombart-Cussac, Antonio
CANCER RESEARCH, 2024, 84 (09)
[32] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Kimmick, G.
Pilehvari, A.
You, W.
Bonilla, G.
Anderson, R.
ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373
[33] CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Deng, Yunfu
Ma, Guangzhi
Li, Wen
Wang, Ting
Zhao, Yaqin
Wu, Qiang
CLINICAL BREAST CANCER, 2018, 18 (05) : E943 - E953
[34] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
Hortobagyi, Gabriel N.
Paluch-Shimon, Shani
Petrakova, Katarina
Villanueva, Cristian
Chan, Arlene
Nusch, Arnd
Yap, Yoon Sim
Hart, Lowell
Favret, Anne
Marschner, Norbert
Sonke, Gabe S.
Ohnstad, Hege Oma
Arteaga, Carlos
Su, Fei
He, Wei
Miller, Michelle Kristine
Stemmer, Salomon M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[35] Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Sahin, Taha Koray
Rizzo, Alessandro
Guven, Deniz Can
Aksoy, Sercan
CANCER TREATMENT REVIEWS, 2025, 135
[36] Study Supports Delay of CDK4/6 Inhibitors Until Second-Line Treatment in Advanced HR+/HER2- Breast Cancer
Rugo, Hope S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 352 - 353
[37] CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort
Javaid, Anadil
Lok, Sheau Wen
Wong, Vanessa
Baron-Hay, Sally
Boyle, Fran
Collins, Ian
Cuff, Katharine
de Boer, Richard
Gately, Lucy
Georgiou, Chloe
Greenberg, Sally
Karki, Bhaskar
Nottage, Michelle
Rainey, Natalie
Torres, Javier
Yeo, Belinda
Devitt, Bianca
Gibbs, Peter
Anton, Angelyn
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 129 - 130
[38] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: A network meta-analysis (NMA) of randomized controlled trials (RCTs).
Husnain, Muhammad
Bin Riaz, Irbaz
Gondal, Farva R.
Malik, Saad
Sipra, Qurat U. I. Ain Riaz
Raina, Ammad
Islam, Mahnoor
Lopes, Gilberto
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Real-world analysis of disease progression after CDK 4/6 inhibitor (CDKi) therapy in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC).
West, Malinda
Kaempf, Andy
Goodyear, Shaun
Kartika, Thomas
Ribkoff, Jessica
Mitri, Zahi Ibrahim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
Fedele, Palma
Cinieri, Saverio
FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239

← 1 2 3 4 5 →